Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: A comparative oncology study in dogs

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Paoloni, Melissa C ^a   Mazcko, Christina ^a   Fox, Elizabeth ^b   Fan, Timothy ^c   Lana, Susan ^d   Kisseberth, William ^e   Vail, David M ^f   Nuckolls, Kaylee ^a   Osborne, Tanasa ^a   Yalkowsy, Samuel ^g   Gustafson, Daniel ^d   Yu, Yunkai ^a   Cao, Liang ^a   Khanna, Chand ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; COMPARATIVE STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMAL RESIDUAL DISEASE; NONHUMAN; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR BIOPSY;

ANIMALS; CELL LINE, TUMOR; COHORT STUDIES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; MALE; OSTEOSARCOMA; SIROLIMUS;

CANIS FAMILIARIS;

EID: 77956205777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011013     Document Type: Article

References (38)

1. Hutson TE, Figlin RA (2007) Renal cell cancer. Cancer J 13: 282-286.
2. Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-1018.
3. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
4. Yao JC (2007) Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21: 163-172.
5. Costa LJ (2007) Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 33: 78-84.
6. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
7. Chon HS, Hu W, Kavanagh JJ (2006) Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 6: 333-363.
8. Tallman MS (2006) New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 19: 311-320.
9. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY (2006) Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 8: 58-70.
10. Williams ME, Densmore JJ (2005) Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 17: 425-431.
11. von Mehren M (2003) New therapeutic strategies for soft tissue sarcomas. Curr Treat Options Oncol 4: 441-451.
12. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537.
13. Seddon BM, Whelan JS (2008) Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs 10: 93-105.
14. Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346.
15. Kasper B, Gil T, Awada A (2007) Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol 19: 336-340.
16. Hansen A, Boshoff C, Lagos D (2007) Kaposi sarcoma as a model of oncogenesis and cancer treatment. Expert Rev Anticancer Ther 7: 211-220.
17. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
18. Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 6: 103-134.
19. Wysocki PJ (2009) mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 9: 231-241.
20. Jiang BH, Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76.
21. Petricoin EF, 3rd, Espina V, Araujo RP, Midura B, Yeung C, et al. (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67: 3431-3440.
22. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940.
23. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrinmediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65: 2406-2411.
24. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972.
25. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
26. Stepkowski SM, Tian L, Wang ME, Qu X, Napoli K, et al. (1997) Sirolimus in transplantation. Arch Immunol Ther Exp (Warsz) 45: 383-390.
27. Hartner WC, Van der Werf WJ, Lodge JP, Gilchrist B, De Fazio SR, et al. (1995) Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine. Transplantation 60: 1347-1350.
28. Collier DS, Calne R, Thiru S, Lim S, Pollard SG, et al. (1990) Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 22: 1674-1675.
29. Knight R, Ferraresso M, Serino F, Katz S, Lewis R, et al. (1993) Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 55: 947-949.
30. Gunji Y, Ochiai T, Sakamoto K, Suzuki T, Nagata M, et al. (1993) Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. Transplant Proc 25: 752-753.
31. Gordon IK, Ye F, Kent MS (2008) Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 69: 1079-1084.
32. Vail D (2004) Veterinary Co-operative Oncology Group. Veterinary and Comparative Oncology 2: 194-213.
33. Bouzas L, Hermida J, Tutor JC (2009) Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: Diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrations. Ups J Med Sci.
34. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, et al. (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15: 6732-6739.
35. Withrow SJ, Powers BE, Straw RC, Wilkins RM (1991) Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res. pp 159-168.
36. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, et al. (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10: 625.
37. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, et al. (2008) Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26: 4172-4179.
38. NCI, NCI-Bioinformatics, Oracle (2002 Fall - [current version 2007 Jan; cited 2008 June]) Cancer Central Clinical Database (C3D) [Internet]. Version 4.5.2.